News Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-12 pm EST			5-day change	1st Jan Change
0.4122 ^USD	-0.79%		+4.09%	+0.49%

07:55am	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI

07:55am	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
07:48am	Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities	PR
Dec. 18	Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial	PU
Dec. 18	Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations	PU
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium	PR
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI
Dec. 08	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement	AQ
Dec. 05	Intensity Therapeutics Gets Extension to Regain Nasdaq Minimum Price Requirement	MT
Dec. 05	Intensity Therapeutics granted 180-day extension	RE
Dec. 05	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement	PR
Dec. 04	Intensity Therapeutics files for offering of up to $30 million common stock - SEC filing	RE
Dec. 04	Intensity Therapeutics announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium	RE
Nov. 06	Intensity Therapeutics : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
Nov. 06	Intensity Therapeutics Q3 net loss narrows to $2.7 mln	RE
Nov. 06	Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	Intensity Therapeutics Prices $4 Million Direct Offering	MT
25-10-31	Intensity Therapeutics, Inc. - Special Call
25-10-31	Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock	PR
25-10-30	Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal	CI
25-09-10	Intensity Therapeutics: Invincible-4 TNBC trial update	RE
25-09-10	Intensity Therapeutics, Inc. Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update	CI
25-09-08	Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-SEP-2025.	CI
25-09-08	Certain Stock Options of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-SEP-2025.	CI
25-09-08	Certain Warrants of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-SEP-2025.	CI
25-09-02	Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Filters